Northwest Biotherapeutics Inc (PK:NWBO)

Mar 21, 2024 11:09 am ET
Northwest Biotherapeutics Appoints Seasoned Business Executive and Investor To Its Board of Directors
BETHESDA, Md., March 21, 2024 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has appointed Mr. Pat Sarma to its Board of Directors effective March 18, 2024.
Feb 06, 2024 08:30 am ET
Northwest Biotherapeutics Moves From Optimization of Flaskworks Prototype to Fabrication of GMP-Compliant Units For Installation, Validation and Final Testing Prior to Regulatory Certification
Accompanied by Broad Patent Coverage
Dec 21, 2023 08:30 am ET
Northwest Biotherapeutics Announces That A Marketing Authorization Application Has Been Submitted To The UK MHRA For DCVax®-L For Glioblastoma
Culmination Of Over 20 Years Of Research And Clinical Development
Nov 22, 2023 08:30 am ET
Northwest Biotherapeutics Provides Update On Final Preparations For Marketing Authorization Application
BETHESDA, Md., Nov. 22, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an update today about the final preparations for the Marketing Authorization Application (MAA) that will be submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company's DCVax®-L treatment for glioblastoma.   
Oct 13, 2023 09:30 am ET
Northwest Biotherapeutics Provides Update On Near Term Plans For Submission of Marketing Authorization Application
BETHESDA, Md., Oct. 13, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, provided an update today about its progress toward submission of a Marketing Authorization Application (MAA) to the Medicines and Healthcare Products Regulatory Agency (MHRA)(the equivalent of the U.S. FDA) in the U.K. for commercial approval of the Company's DCVax®-L treatment for glioblastoma.     
Sep 12, 2023 10:00 am ET
Northwest Biotherapeutics Announces That Dr. Linda Liau Has Joined The Company's Scientific Advisory Board
BETHESDA, Md., Sept. 12, 2023 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announces that Dr. Linda Liau, MD, PhD, MBA has joined the Company's Scientific Advisory Board (SAB). 
Mar 20, 2023 07:46 pm ET
Northwest Biotherapeutics and Advent BioServices Announce Receipt of License for Commercial Manufacturing at Sawston, U.K. Facility
One of the First UK Licenses for Commercial Manufacturing of Cell Therapy Products;
Mar 11, 2023 05:04 pm ET
Northwest Biotherapeutics Announces That It Has No Banking Relationship With SVB
BETHESDA, Md., March 11, 2023 /PRNewswire/ --  Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has no banking relationship with Silicon Valley Bank (SVB) and no funds on deposit at SVB. 
Jan 06, 2023 08:15 am ET
Northwest Biotherapeutics Announces Positive Votes At Annual Meeting; Reviews 2022 Progress and Looks Forward to Strong 2023
78% Of All Shares Were Voted; Proposals Received ≥90% of Votes Cast
Nov 17, 2022 11:36 am ET
Northwest Biotherapeutics Reports Positive Top-Line Results From Phase 3 Trial of DCVax®-L for Glioblastoma
Both Median Survival and "Long Tail" of Extended Survival Were Increased In Both Newly Diagnosed and Recurrent Glioblastoma
Aug 23, 2022 09:39 am ET
Northwest Biotherapeutics Announces Approval of Pediatric Investigation Plan (PIP) by MHRA
 PIP Approval Is A Pre-Requisite for Application for Approval of A New Medicine for Adult Patients
Jun 05, 2022 09:23 pm ET
Northwest Biotherapeutics Announces Presentations On DCVax®-L Personalized Vaccines, Manufacturing and Scale-Up, and DCVax®-L Clinical Program
BETHESDA, Md., June 5, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that yesterday on June 4, 2022, in the Industry Expert Theater during the ASCO 2022 conference, Dr. Marnix Bosch made a presentation discussing the Company's DCVax-L technology for personalized dendritic cell vaccines, the Sawston, UK facility, the manufacturing technology, the development of automation, and preparations for manufacturing scale-up. In addition, a video presentation about the D
May 10, 2022 10:19 am ET
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma Today At New York Academy of Sciences To Be Available Online As Well
BETHESDA, Md., May 10, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that, as previously announced, a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made today at 11:10 a.m., at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences.  The presentation will be made by Dr. Paul Mulholland of University College Hospital.  
May 04, 2022 11:35 am ET
Presentation About Phase 3 Trial of DCVax®-L for Glioblastoma To Be Made At New York Academy Of Sciences
BETHESDA, Md., May 4, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, reported that a presentation entitled "Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination for Glioblastoma" will be made on May 10, 2022 at 11:10 a.m., by Dr. Linda Liau at the Frontiers of Cancer Immunotherapy Conference of the New York Academy of Sciences.
Feb 17, 2022 08:20 am ET
Northwest Biotherapeutics Announces Commencement Of Cancer Vaccine Production At Its Sawston, UK Facility
BETHESDA, Md., Feb. 17, 2022 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced commencement of production of its first dendritic cell cancer vaccine for a compassionate use patient at its recently licensed production facility in Sawston, UK.
Dec 21, 2021 08:24 am ET
Northwest Biotherapeutics Announces MHRA Approval Of License for GMP Manufacturing At Sawston, UK Facility
BETHESDA, Md., Dec. 21, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that approval has been received from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a license for manufacture of GMP (clinical grade) cell therapy products at its Sawston, UK facility.
Nov 29, 2021 09:38 am ET
Northwest Biotherapeutics Announces $15 Million Financing
BETHESDA, Md., Nov. 29, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the closing of a $15 million financing on November 22, 2021, which brought the Company's cash reserves above $20 million.
Oct 28, 2021 11:42 am ET
Northwest Biotherapeutics Announces HTA License Issued and MHRA Inspection Conducted for Sawston, UK Facility
BETHESDA, Md., Oct. 28, 2021 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced the completion of two key milestones which are required for production of DCVax products at the Company's manufacturing facility in Sawston, UK, and which have been a major focus since the completion of initial construction last year.
Jul 24, 2020 09:31 am ET
Northwest Biotherapeutics Announces Completion of Phase 3 Trial Sites' Databases
BETHESDA, Md., July 24, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the data collection from all of the clinical trial sites for the Company's Phase 3 trial of DCVax®-L for Glioblastoma brain cancer (the "Trial") has been completed and all of the sites have signed off on the locking of their data.
Jun 02, 2020 09:35 am ET
NW Bio Provides Update On Projected Timing For Data Lock For Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer
BETHESDA, Md., June 2, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today reported progress toward data lock for the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer. 
Apr 18, 2020 01:05 pm ET
NW Bio To Discuss Projected Schedule For Data Lock, Unblinding and Top Line Data From Its Phase 3 Clinical Trial At Annual Shareholder Meeting
BETHESDA, Md., April 18, 2020 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that its CEO, Linda Powers, will discuss the projected schedule for reaching data lock, unblinding and reporting of top line data from its 331-patient Phase 3 trial of DCVax®-L for Glioblastoma brain cancer at the Company's 2019 Annual Meeting.  The Meeting is being held virtually due to the current public health crisis. 
Oct 10, 2019 05:39 pm ET
NW Bio Moves Forward With SEC Settlement
BETHESDA, Md., Oct. 10, 2019 /PRNewswire/ -- Northwest Biotherapeutics (NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a settlement with the SEC.
Sep 04, 2019 09:25 am ET
NW Bio Expands Senior Management Team With Dr. Kevin Duffy As Vice President, Medical Affairs & External Collaborations
BETHESDA, Md., Sept. 4, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has expanded its senior management team with the addition of Dr. Kevin T. Duffy as Vice President, Medical Affairs and External Collaborations.
Feb 26, 2019 08:48 am ET
NW Bio Hires David Innes As Vice President, Investor Relations
BETHESDA, Md., Feb. 26, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has hired David Innes as Vice President, Investor Relations.
Feb 08, 2019 07:25 am ET
NW Bio Releases Voting Results From Annual Shareholders' Meeting
BETHESDA, Md., Feb. 8, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) — ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today released the final voting results from the Annual Shareholder Meeting held on February 2, 2019.
Jan 25, 2019 07:59 am ET
Presentation By NWBio CEO At The Phacilitate Leaders World 2019 Conference
BETHESDA, Md., Jan. 25, 2019 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its CEO, Linda Powers, presented at the Phacilitate Leaders World 2019 Conference in Miami, Florida. The slide deck from this presentation can be found on the Company's website at www.nwbio.com.  
Dec 14, 2018 07:59 am ET
NW Bio Announces That UK Property Transaction Has Closed, Including Funding of Approximately $47.3 Million Gross Proceeds
BETHESDA, Md., Dec. 14, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that the package transaction involving the Company's UK property, which the Company announced earlier this week, closed today in the UK.  The closing included the transaction elements previously announced:
Dec 11, 2018 07:32 am ET
NW Bio Announces Non-Dilutive Funding of Approximately $47.3 Million Through UK Property Transaction
BETHESDA, Md., Dec. 11, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that it has entered into agreements with a large multi-national corporation for a package transaction involving the Company's property located near Cambridge, UK.  Pursuant to these agreements,
Nov 19, 2018 09:04 am ET
Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma Presented at Society for Neuro-Oncology Conference
BETHESDA, Md., Nov. 19, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that updated blinded interim data from the Phase 3 trial of DCVax®-L for Glioblastoma brain cancer were presented by Dr. Linda Liau at the 23rd Annual Meeting of the Society for Neuro-Oncology. The updated data through October 2018 have continued to mature since the prior interim data collection in March 2017, and indicate encouraging patient survival. 
Nov 13, 2018 07:30 am ET
NW Bio Announces $5 Million Bridge Funding
BETHESDA, Md., Nov. 13, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that on November 7, 2018, it completed an aggregate financing of $5 million from long term angel investors. 
Aug 28, 2018 02:08 pm ET
NW Bio Announces Upcoming Presentation By Dr. Marnix Bosch At Immuno-Oncology Summit
BETHESDA, Md., Aug. 28, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio is presenting at 8:00 pm Wednesday evening, August 29, at the Immuno-Oncology Summit being held at the Seaport World Trade Center, 1 Seaport Boulevard in Boston, Massachusetts.  The title of his presentation is Clinical Development Of Dendritic Cell-Based Immunotherapies for Cancer.  Dr. Bosch will discuss recently published i
May 31, 2018 11:15 am ET
NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO
BETHESDA, Md., May 31, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 3, at 4:15 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will discuss the interim data that was published on May 29 from the Company's Phase 3 trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer.
May 31, 2018 11:15 am ET
NW Bio To Discuss Interim Phase 3 Trial Data In Industry Theater Session During ASCO
BETHESDA, Md., May 31, 2018 /CNW/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that on Sunday, June 3, at 4:15 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, Chief Technical Officer of NW Bio, will discuss the interim data that was published on May 29 from the Company's Phase 3 trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer.
May 29, 2018 10:24 am ET
NWBio Announces Scientific Publication of Interim Survival Data From Phase 3 Trial of DCVax®-L for Glioblastoma Brain Cancer
BETHESDA, Md., May 29, 2018 /PRNewswire-USNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today the publication of interim blinded survival data from its Phase 3 clinical trial of DCVax®-L for newly diagnosed Glioblastoma brain cancer.  The data were collected by the independent contract research organization managing the trial, tabulated by an independent statistical firm and published with 69 co-authors in the peer reviewed Journal of Translational Medicine (JTM).
May 01, 2018 08:45 am ET
NW Bio Releases Vote Tallies From Special Shareholder Meeting
BETHESDA, Md., May 1, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today released the vote tallies for the three proposals on the ballot at its Special Meeting of Shareholders held last Friday afternoon in Washington, DC.
Apr 30, 2018 08:45 am ET
NW Bio Announces Additional Funding
BETHESDA, Md., April 30, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that its CEO, Linda Powers, increased her funding to the Company by $1 million, reaching a total of $5.4 million this year to date.    
Feb 20, 2018 01:25 pm ET
NW Bio Congratulates Cognate BioServices On Its Management Buyout
BETHESDA, Md., Feb. 20, 2018 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, congratulated Cognate BioServices, the contract manufacturer of NWBio's DCVax® products, on the Management Buyout of Cognate supported by global institutional investors, which Cognate announced today.
Dec 19, 2017 11:32 am ET
NW Bio Announces Regulation D Offering for Accredited Investors
BETHESDA, Md., Dec. 19, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) -- (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is commencing a general solicitation Regulation D offering  to accredited investors.  The Offering will remain open for execution of subscription agreements until 5:30 pm EST on Wednesday, December 27, 2017, and the closing is expected to take place on Friday, December 29, 2017.
Oct 30, 2017 10:45 am ET
NW Bio Reports Favorable Results and Progress In Resolving Lawsuits
BETHESDA, Md., Oct. 30, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company's periodic filings.
Oct 25, 2017 10:46 am ET
NW Bio Reports Favorable Results and Progress In Resolving Lawsuits
BETHESDA, Md., Oct. 25, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, is pleased to report meaningful progress in resolving four lawsuits that were brought against it as reported in the Company's periodic filings.
Oct 17, 2017 12:44 pm ET
NW Bio Leases Out Warehouse On UK Property to Major Commodities Distribution Firm
BETHESDA, Md., Oct. 17, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced it has leased an existing warehouse on the Company's property in the UK to Commodity Centre Group, a commodity storage and distribution firm domiciled in the UK. The lease represents an initial step in realizing value from the Company's property while the Company continues development of a facility on the site for manufacturing of its DCVax products for the UK and the Europe-wide re
Sep 20, 2017 09:00 am ET
NW BIO Announces Registered Direct Offering Of $1.75 Million
BETHESDA, Md., Sept. 20, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $1.75 million.
Sep 01, 2017 03:49 pm ET
DCVax® Clinical Program Updates Presented By Dr. Marnix Bosch At Boston Scientific Conference
BETHESDA, Md., Sept. 1, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix L. Bosch, MBA, PhD and Chief Technical Officer of NW Bio presented an update on the Phase III Trial of DCVax®-L for newly diagnosed GBM and the DCVax®-Direct Trials at the Cambridge Healthtech Institute's Immuno-Oncology Summit in Boston, Massachusetts yesterday.  There was no webcast.  Dr. Bosch has posted the PowerPoint from this presentation on the NW Bio website at www.nwbi
Jun 22, 2017 12:41 pm ET
NWBio Closes 3-Year Convertible Debt Exchange and Financing, and Completes Payoff of Last $5 Million of 2014 Bonds
BETHESDA, Md., June 22, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that it has closed a convertible debt exchange and financing transaction with a non-affiliated investor and has completed the payoff of the last $5 million of principal and $175,000 of interest on bonds from a 2014 financing. 
Jun 05, 2017 10:17 am ET
Dr. Marnix Bosch To Present Updates About DCVax® Clinical Programs Today
BETHESDA, Md., June 5, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that this afternoon at 3:00 p.m. Central Time in the Industry Expert Theater in the Exhibit Hall at the ASCO Conference in the McCormick Place Convention Center in Chicago, Illinois, Dr. Marnix L. Bosch, MBA, PhD and Chief Technical Officer of NW Bio, will deliver a webcast update on the Company's clinical trial programs.
Mar 23, 2017 01:49 pm ET
NW Bio Has Closed On Its Registered Direct Offering Of $7.5 Million With Institutional Investors
BETHESDA, Md., March 23, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that yesterday it closed on the $7.5 million financing it announced last Friday, March 17, 2017.
Mar 17, 2017 10:00 am ET
NW BIO Announces Registered Direct Offering Of $7.5 Million
BETHESDA, Md., March 17, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $7.5 million.
Mar 10, 2017 08:15 am ET
NW Bio Reaches Agreement With Convertible Note Holders
BETHESDA, Md., March 10, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that it has signed a Note Repurchase Agreement with a group of bondholders affiliated with Whitebox Advisors ("Whitebox"), holder of $11 million of NW Bio convertible senior notes.
Feb 06, 2017 09:30 am ET
NW Bio Announces Lifting of Clinical Hold on DCVax®-L Phase III Trial By FDA; Progression-Free Survival Events Reached; Overall Survival Events Not Yet Reached
BETHESDA, Md., Feb. 6, 2017 /PRNewswire/ -- Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided a further update about the Company's Phase III trial of DCVax®-L for Glioblastoma multiforme ("GBM") brain cancer (the "Trial").  The Company announced that the partial clinical hold on the Trial has been lifted by the FDA, and that the Trial has accumulated a sufficient number of events toward the progression-free survival ("PFS") endpoint, but not yet for the overall s
Jan 18, 2017 03:28 pm ET
NW Bio Presenting At Phacilitate Immunotherapy World Conference
BETHESDA, Md., Jan. 18, 2017 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, will present at the Phacilitate Immunotherapy World Conference on Thursday, January 19, 2017, at the Hyatt Regency Hotel in Miami, Florida.
Dec 20, 2016 09:29 am ET
NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $10.0 MILLION WITH INSTITUTIONAL INVESTORS
BETHESDA, Md., Dec. 20, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with institutional investors for a registered direct offering with gross proceeds of $10 million.
Dec 19, 2016 09:39 am ET
NW Bio Announces Initiation Of Trading On The OTCQB Marketplace Starting On Monday Morning, December 19, 2016
BETHESDA, Md., Dec. 19, 2016 /PRNewswire/ -- Northwest Biotherapeutics (Nasdaq: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that its common stock will begin trading on the OTC Market Group's OTCQB marketplace effective at the open of the market on Monday, December 19, 2016.  The Trading symbol will remain NWBO.
Dec 08, 2016 02:04 pm ET
NW Bio Provides Update About Phase 3 Trial Of DCVax®-L for Newly Diagnosed Glioblastoma Multiforme Brain Cancer
BETHESDA, Md., Dec. 8, 2016 /PRNewswire/ -- Northwest Biotherapeutics (Nasdaq: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today provided an update about the Company's Phase 3 trial of DCVax®-L for Glioblastome multiforme (GBM) brain cancer (the "Trial").  The Company announced that 331 of the planned 348 patients have been enrolled in the Trial, and that data "events" have been accumulating towards the endpoints of the Trial.
Dec 07, 2016 08:00 pm ET
NW Bio Announces Decision to Voluntarily Withdraw from Nasdaq Listing and Begin Trading on OTC Market
BETHESDA, Md., Dec. 7, 2016 /PRNewswire/ -- Northwest Biotherapeutics (Nasdaq: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Nasdaq Staff has not accepted the Company's plan of remediation for certain violations of Listing Rules previously reported, and the Company has notified Nasdaq of its intention to voluntarily withdraw the Company's common stock from listing on Nasdaq.  Upon withdrawal from Nasdaq, the Company plans to begin trading on the over-the-counter (OTC) market.
Nov 17, 2016 08:15 am ET
NW Bio Announces Phase II Clinical Trial Program Combining DCVax®-L and Pembrolizumab (Keytruda®) for Colorectal Cancer
BETHESDA, Md., Nov. 17, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today joined the University Medical Center (UMC) of the Johannes Gutenberg University Mainz in Germany in announcing a Phase II clinical trial program combining DCVax®-L and Pembrolizumab (Keytruda®) for colorectal cancer with liver metastases.
Oct 21, 2016 10:45 am ET
NW BIO Announces Registered Direct Offering
BETHESDA, Md., Oct. 21, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into a definitive agreement with an institutional investor for a registered direct offering with gross proceeds of approximately $5million. The proceeds will be used in connection with upcoming Phase II clinical trials.
Sep 29, 2016 10:26 am ET
NW Bio Presents Further DCVax®-Direct Phase I Trial Information On Individual Patient Survival At NY Cancer Immunotherapy Conference
BETHESDA, Md., Sept. 29, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, Chief Technical Officer of NW Bio, presented additional information relating to the DCVax®-Direct Phase I Trial in a poster presentation at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, being held from September 25th through    September 28th in New York City.
Sep 21, 2016 02:51 pm ET
NW Bio Presents Updated Data From DCVax®-Direct Phase I Trial At 5th Annual SMi Cancer Vaccines Conference in London
BETHESDA, Md., Sept. 21, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO)("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced that Dr. Marnix Bosch, Chief Technical Officer, today presented an updated and more detailed analysis of the Phase I DCVax®-Direct Trial data at the 5th Annual SMi Cancer Vaccines Conference in London, England.
Sep 06, 2016 09:55 am ET
NASDAQ Accepts NW Bio Remediation Plan For Shares and Warrants Previously Issued to Cognate BioServices
BETHESDA, Md., Sept. 6, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio" or the "Company"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that Nasdaq has accepted NW Bio's proposed remediation plan to resolve Nasdaq's finding, previously disclosed by the Company, that NW Bio failed to comply with certain Nasdaq listing rules with regard to certain securities issuances to Cognate BioServices, Inc. ("Cognate").  As a result of this acceptance, Nasdaq has notified the Company that it has regained complianc
Jul 05, 2016 10:00 am ET
NW BIO ANNOUNCES A REGISTERED DIRECT OFFERING OF $3.7 MILLION WITH NEW INSTITUTIONAL INVESTORS
BETHESDA, Md., July 5, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with two new institutional investors for a registered direct offering with gross proceeds of $3.7 million.
Jun 30, 2016 06:25 pm ET
NW Bio Enters First 180-Day Grace Period Relating To Non-Compliance With Nasdaq $1.00 Per Share Bid Requirement
BETHESDA, Md., June 30, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced it had filed an 8-K today relating to two outstanding Nasdaq issues, including progress on a remediation plan relating to certain prior stock issuances.
Jun 13, 2016 10:15 am ET
NW Bio Announces Scientific Advisory Board
BETHESDA, Md., June 13, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immunotherapies for solid tumor cancers, announced its Scientific Advisory Board (SAB) comprised of leading experts in immunotherapies and oncology from both the U.S. and Europe. 
May 02, 2016 06:00 pm ET
NW Bio Announces Operations Updates
BETHESDA, Md., May 2, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) ("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today an operations update in regard to its Phase I and II Trials, Scientific Advisory Board and Nasdaq compliance.
Feb 29, 2016 10:58 am ET
NW BIO Announces Registered Direct Offering Of Up To $27.6 Million With Existing Institutional Investors
BETHESDA, Md., Feb. 29, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it has entered into definitive agreements with current institutional investors for a registered direct offering with gross proceeds of up to approximately $27.6 million, assuming exercise in full of the overallotment option described below.
Jan 25, 2016 12:42 pm ET
NW Bio Presenting At Phacilitate Immunotherapy World Forum
BETHESDA, Md., Jan. 25, 2016 /PRNewswire/ -- Northwest Biotherapeutics, Inc. (NASDAQ: NWBO)("NW Bio"), a U.S. biotechnology company developing DCVax® personalized immune therapies for operable and inoperable solid tumor cancers, announced today that CEO Linda Powers will chair the morning plenary session and present at the Phacilitate Immunotherapy World Forum on Tuesday, January 26, 2016, at the Grand Hyatt Hotel in Washington DC.
Jan 25, 2016 09:29 am ET
NW Bio Announces Appointment Of Two New Independent Directors With Biotech/Pharma Expertise and Cybersecurity/Investigations Expertise
BETHESDA, Md., Jan. 25, 2016 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that it is expanding its Board of Directors through the appointment of Ms. Susan Bayh and Ambassador Cofer Black as independent Directors.  Neither Ms. Bayh nor Ambassador Black has worked with the Company previously. 

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More